Avacta Group (AVCT) Competitors GBX 34 +1.00 (+3.03%) As of 05/2/2025 11:55 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesBuy This Stock AVCT vs. SLN, PRTC, OXB, HZD, FARN, VRP, ARIX, CIR, 4BB, and BVXPShould you be buying Avacta Group stock or one of its competitors? The main competitors of Avacta Group include Silence Therapeutics (SLN), PureTech Health (PRTC), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Faron Pharmaceuticals Oy (FARN), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), Circassia Group (CIR), 4basebio (4BB), and Bioventix (BVXP). These companies are all part of the "biotechnology" industry. Avacta Group vs. Silence Therapeutics PureTech Health Oxford Biomedica Horizon Discovery Group plc (HZD.L) Faron Pharmaceuticals Oy Verona Pharma plc (VRP.L) Arix Bioscience Circassia Group 4basebio Bioventix Avacta Group (LON:AVCT) and Silence Therapeutics (LON:SLN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk. Is AVCT or SLN more profitable? Silence Therapeutics has a net margin of 0.00% compared to Avacta Group's net margin of -114.45%. Silence Therapeutics' return on equity of 0.00% beat Avacta Group's return on equity.Company Net Margins Return on Equity Return on Assets Avacta Group-114.45% -74.00% -21.80% Silence Therapeutics N/A N/A N/A Does the MarketBeat Community believe in AVCT or SLN? Avacta Group received 9 more outperform votes than Silence Therapeutics when rated by MarketBeat users. However, 68.81% of users gave Silence Therapeutics an outperform vote while only 67.30% of users gave Avacta Group an outperform vote. CompanyUnderperformOutperformAvacta GroupOutperform Votes21267.30% Underperform Votes10332.70% Silence TherapeuticsOutperform Votes20368.81% Underperform Votes9231.19% Which has higher earnings and valuation, AVCT or SLN? Silence Therapeutics has lower revenue, but higher earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvacta Group£26.29M4.91-£30.08M-£7.77-4.38Silence Therapeutics£11.35M0.00N/A-£48.60N/A Do insiders & institutionals believe in AVCT or SLN? 10.2% of Avacta Group shares are owned by institutional investors. 32.9% of Avacta Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media refer more to AVCT or SLN? In the previous week, Avacta Group had 3 more articles in the media than Silence Therapeutics. MarketBeat recorded 3 mentions for Avacta Group and 0 mentions for Silence Therapeutics. Avacta Group's average media sentiment score of 0.00 equaled Silence Therapeutics'average media sentiment score. Company Overall Sentiment Avacta Group Neutral Silence Therapeutics Neutral SummaryAvacta Group beats Silence Therapeutics on 7 of the 11 factors compared between the two stocks. Get Avacta Group News Delivered to You Automatically Sign up to receive the latest news and ratings for AVCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVCT vs. The Competition Export to ExcelMetricAvacta GroupBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£129.17M£125.51M£5.55B£2.60BDividend Yield3.97%3.69%5.09%4.98%P/E Ratio-4.383.2722.69133.85Price / Sales4.914,272.58404.28240,531.85Price / Cash15.0013.0238.1828.01Price / Book2.3134.206.794.56Net Income-£30.08M-£90.45M£3.22B£5.86B7 Day Performance7.94%1.41%3.37%3.43%1 Month Performance-1.45%5.34%6.95%12.39%1 Year Performance-25.27%92.77%16.13%113.22% Avacta Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVCTAvacta GroupN/AGBX 34+3.0%N/A-26.9%£129.17M£26.29M-4.38120SLNSilence TherapeuticsN/AN/AN/AN/A£480.35M£11.35M-11.01100High Trading VolumePRTCPureTech Health2.0367 of 5 starsGBX 129.05+2.6%GBX 455+252.6%-39.2%£387.65M£521,320.79-5.29300Positive NewsGap DownOXBOxford Biomedica2.453 of 5 starsGBX 299+0.5%GBX 560+87.3%-1.7%£317.84M£98.31M-2.22891News CoverageGap DownHZDHorizon Discovery Group plc (HZD.L)N/AN/AN/AN/A£302.98M£54.63M-33.55416FARNFaron Pharmaceuticals OyN/AGBX 200.10-2.4%N/A+32.5%£268.64MN/A-5.3534VRPVerona Pharma plc (VRP.L)N/AN/AN/AN/A£228MN/A-1.6822Gap UpARIXArix BioscienceN/AN/AN/AN/A£183.73M£14.16M1,290.919News CoverageCIRCircassia GroupN/AN/AN/AN/A£142.66M£27.90M3,400.00111Gap Down4BB4basebio2.2244 of 5 starsGBX 1,101-2.1%GBX 1,600+45.3%+2.4%£141.04M£311,000.00-1,411.54101BVXPBioventixN/AGBX 2,589+0.5%N/A-37.8%£135.57M£13.65M16.7412Positive News Related Companies and Tools Related Companies Silence Therapeutics Alternatives PureTech Health Alternatives Oxford Biomedica Alternatives Horizon Discovery Group plc (HZD.L) Alternatives Faron Pharmaceuticals Oy Alternatives Verona Pharma plc (VRP.L) Alternatives Arix Bioscience Alternatives Circassia Group Alternatives 4basebio Alternatives Bioventix Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:AVCT) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredMassive red flag about American consumerWhy is the U.S. Dollar suddenly crashing? Pundits on either side of the aisle have been warning that the U....Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avacta Group Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Avacta Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
